Patients with heart failure with preserved ejection fraction have a equally high risk for mortality and re-hospitalization as those with reduced ejection fraction. Effective management strategies are critically needed to be established for this type of heart failure. These patients have more hypertensive and ischemic etiology than those with reduced ejection fraction. The investigators hypothesis is that Ca channel blocker nifedipine can improve the heart failure clinical composite response endpoint compared with the conventional treatment in patients with heart failure with hypertension and/or coronary artery disease and preserved ejection fraction (\>=50%) by echocardiography. This study is multi-center, prospective, randomized, open-label, and blinded-endpoint design.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
226
Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
Conventional therapy
Hokkaido Univestity Hospital
Sapporo, Japan
Heart failure clinical composite response endpoint
Time frame: up to 53 months
Death
Time frame: up to 53 months
Cardiovascular death
Time frame: up to 53 months
Hospital admission
Time frame: up to 53 months
Hospital admission for cardiovascular disease
Time frame: up to 53 months
Hospital admission for worsening heart failure
Time frame: up to 53 months
Hospital admission for acute myocardial infarction, angina, coronary artery bypass grafting and percutaneous coronary intervention
Time frame: up to 53 months
Stroke
Time frame: up to 53 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.